Approximately 30–50 % of colorectal tumors are associated with an abnormal KRAS gene, signifying that nearly half of patients with colorectal cancer (CRC) might respond to anti-epidermal growth factor receptor (EGFR) treatment, and the other half might not [65]. The gene discussed is EGFR; the disease is colorectal neoplasm.